| Literature DB >> 28454244 |
Minoru Tomizawa1, Fuminobu Shinozaki2, Yasufumi Motoyoshi3, Takao Sugiyama4, Shigenori Yamamoto5, Naoki Ishige6.
Abstract
Resistance to sorafenib in hepatocellular carcinoma (HCC) cells exhibiting stemness was evaluated using a sphere formation assay. A hepatocyte selection medium (HSM) deficient in glucose and arginine was used to suppress the proliferation of cell spheres composed of HLF and PLC/PRF/5 HCC cells, which were subjected to a sphere formation assay. Cell spheres were cultured with sorafenib and subjected to a cell proliferation assay and the expression levels of cytochrome P450 (CYP3A4) were analyzed in RNA extracted from sphere-forming cells using reverse transcription-quantitative polymerase chain reaction. Sphere-forming PLC/PRF/5 cells were more resistant to sorafenib, as compared with control cells, exhibiting higher expression levels of CYP3A4. When cultured in HSM, suppressed proliferation was observed in the sphere-forming PLC/PRF/5 cells and in the control cells, with no significant variation between them. The results suggest that deprivation of glucose and arginine is a potential novel treatment for HCC.Entities:
Keywords: arginine; cytochrome P450; glucose; sorafenib; sphere formation assay
Year: 2017 PMID: 28454244 PMCID: PMC5403635 DOI: 10.3892/ol.2017.5565
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967